quator 2,5 mg filmovertrukne tabletter
sandoz a/s - tadalafil - filmovertrukne tabletter - 2,5 mg
quator 10 mg filmovertrukne tabletter
sandoz a/s - tadalafil - filmovertrukne tabletter - 10 mg
quator 20 mg filmovertrukne tabletter
sandoz a/s - tadalafil - filmovertrukne tabletter - 20 mg
quator 5 mg filmovertrukne tabletter
sandoz a/s - tadalafil - filmovertrukne tabletter - 5 mg
faberka 20 mg filmovertrukne tabletter
stada arzneimittel ag - tadalafil - filmovertrukne tabletter - 20 mg
volibris
glaxosmithkline (ireland) limited - ambrisentan - hypertension, lunge - antihypertensiva, - volibris is indicated for treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment (see section 5. efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease. volibris is indicated for treatment of pah in adolescents and children (aged 8 to less than 18 years) of who functional class (fc) ii to iii including use in combination treatment. efficacy has been shown in ipah, familial, corrected congenital and in pah associated with connective tissue disease (see section 5.
ambrisentan mylan
mylan s.a.s - ambrisentan - hypertension, lunge - antihypertensiva, - ambrisentan mylan er indiceret til behandling af pulmonal arteriel hypertension (pah) hos voksne patienter, som funktionel class (fc) ii til iii, herunder til brug i kombination behandling. effektivitet er blevet vist i idiopatisk pah (ipah) og i pah associeret med bindevævssygdom. ambrisentan mylan er indiceret til behandling af pulmonal arteriel hypertension (pah) hos voksne patienter, som funktionel class (fc) ii til iii, herunder til brug i kombination behandling. effektivitet er blevet vist i idiopatisk pah (ipah) og i pah associeret med bindevævssygdom.
ambrisentan "teva" 5 mg filmovertrukne tabletter
teva b.v. - ambrisentan - filmovertrukne tabletter - 5 mg
nipruss 60 mg pulver til infusionsvæske, opløsning
Øresund pharma aps - natriumnitroprussiddihydrat - pulver til infusionsvæske, opløsning - 60 mg
adempas
bayer ag - riociguat - hypertension, lunge - antihypertensive midler til pulmonal arteriel hypertension - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. effekten har været vist i en pah befolkningen, herunder aetiologies af idiopatisk eller arvelige pah eller pah, der er forbundet med bindevævssygdom. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.